Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Combined Central and Peripheral Demyelination (CPPD) Syndrome After COVID-19 Vaccination
General Neurology
P4 - Poster Session 4 (11:45 AM-12:45 PM)
4-008
Combined Central Nervous System and Peripheral Nervous System Demyelination (CCPD) is a rare phenomenon whose pathogenesis remains largely unknown. The aim of this report is to describe a case of CCPD with the clinical features, diagnostics results, treatments and outcomes.
Describe a novel case of combined central and peripheral demyelinating disease.
A 50-year-old female, without remarkable medical history initially presented with subacute right sided weakness, dysarthria and ataxia as well as hand and foot paresthesias. Brain MRI demonstrated bilateral enhancing lesions in midbrain tegmentum. Extensive studies including CSF basic cell counts, cytology, cytometry, and paraneoplastic/autoimmune panel, heavy metals testing were all nonconclusive. Serum testing for ganglioside disorders and nodopathies was negative. She was treated with a three-day course of high dose IV steroids with significant improvement of her symptoms. One month later, the patient experienced short episodes of severe ataxia and weakness lasting 10-15 seconds despite improvement in midbrain lesion on MRI brain. Additionally, her paresthesias worsened. Nerve conduction studies were performed and demonstrated a length-dependent, sensorimotor, predominately demyelinating polyneuropathy. The patient was empirically treated with a second round of IV steroids with significant improvement.
N/A
CCPD cases are rarely reported likely due to being underdiagnosed with unclear pathologies and guidelines for treatment. This case exhibits a midbrain demyelinating lesion followed by sensorimotor and demyelinating polyneuropathy. COVID-19 infection has been linked to both acute and central peripheral demyelinating pathologies. Retrospectively, three months before developing her symptoms, our patient acquired COVID-19 infection. One month prior to symptom onset she received Ad26COV2.S Janssen vaccination. Development of deficits after vaccination rather than after the viral infection may suggest a role for the immune complex mechanisms in CPPD pathogenesis, a theory that has yet to be verified with future cohort studies and advanced laboratory testing.
Authors/Disclosures
Lydia Kauffman, MD (Penn State Milton S. Hershey Medical Center)
PRESENTER
Dr. Kauffman has nothing to disclose.
Nader El Seblani, MD, PhD (Penn State University) Dr. El Seblani has nothing to disclose.
James Grogan, MD (Pennsylvania State University Hershey Medical Center) Dr. Grogan has nothing to disclose.
Jikku Jose Zachariah, DO (Pennsylvania State University-Hershey Medical Center) Dr. Zachariah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS, Sanofi.
No disclosure on file
Rae E. Bacharach, DO (Penn State University, Milton S Hershey Medical Center) Dr. Bacharach has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology.